Barclays Maintained Qorvo (QRVO) As “Equal-Weight”; Has Target Price per Share Of $87; Affimed NV (AFMD) Shorts Down By 1.3%

February 1, 2018 - By Richard Conner

Among 29 analysts covering Qorvo Inc (NASDAQ:QRVO), 12 have Buy rating, 2 Sell and 15 Hold. Therefore 41% are positive. Qorvo Inc has $9500 highest and $42 lowest target. $74.45’s average target is 3.73% above currents $71.77 stock price. Qorvo Inc had 89 analyst reports since July 22, 2015 according to SRatingsIntel. Raymond James downgraded the shares of QRVO in report on Tuesday, April 19 to “Outperform” rating. The rating was maintained by Ascendiant Capital Markets on Thursday, July 30 with “Buy”. BMO Capital Markets downgraded Qorvo, Inc. (NASDAQ:QRVO) on Thursday, February 2 to “Market Perform” rating. The rating was maintained by KeyBanc Capital Markets on Wednesday, October 11 with “Hold”. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, November 2 report. The firm earned “Hold” rating on Sunday, October 8 by Mizuho. The firm has “Buy” rating by Charter Equity given on Wednesday, March 15. The firm has “Overweight” rating given on Monday, October 24 by JP Morgan. The stock has “Market Perform” rating by Cowen & Co on Friday, November 4. The firm has “Equal Weight” rating given on Thursday, July 30 by Barclays Capital.

Affimed NV (NASDAQ:AFMD) had a decrease of 1.3% in short interest. AFMD’s SI was 340,800 shares in February as released by FINRA. Its down 1.3% from 345,300 shares previously. With 215,400 avg volume, 2 days are for Affimed NV (NASDAQ:AFMD)’s short sellers to cover AFMD’s short positions. The SI to Affimed NV’s float is 1.23%. The stock decreased 1.85% or $0.025 during the last trading session, reaching $1.325. About 181,052 shares traded. Affimed N.V. (NASDAQ:AFMD) has declined 19.09% since February 1, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Analysts await Qorvo, Inc. (NASDAQ:QRVO) to report earnings on February, 7. They expect $1.43 earnings per share, up 17.21% or $0.21 from last year’s $1.22 per share. QRVO’s profit will be $181.81 million for 12.55 P/E if the $1.43 EPS becomes a reality. After $1.33 actual earnings per share reported by Qorvo, Inc. for the previous quarter, Wall Street now forecasts 7.52% EPS growth.

Qorvo, Inc. provides radio frequency solutions and technologies for mobile device, infrastructure, and defense and aerospace applications worldwide. The company has market cap of $9.13 billion. It operates through Mobile Products (MP) and Infrastructure and Defense Products (IDP) divisions. It currently has negative earnings. The MP segment offers cellular RF and WiFi solutions, bulk acoustic wave (BAW) and surface acoustic wave (SAW) filters, power amplifiers (PA), low noise amplifiers, switches, multi-band PAs and transmit modules, RF power management integrated circuits, diversity receive modules, antenna switch modules, antenna tuning and control solutions, modules incorporating PAs and duplexers, and modules incorporating switches, PAs, and duplexers.

The stock increased 1.56% or $1.1 during the last trading session, reaching $71.77. About 3.93M shares traded or 129.31% up from the average. Qorvo, Inc. (NASDAQ:QRVO) has risen 60.08% since February 1, 2017 and is uptrending. It has outperformed by 43.38% the S&P500.

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, August 31 by Jefferies. The rating was downgraded by Leerink Swann on Friday, August 12 to “Market Perform”. The stock has “Hold” rating by Jefferies on Wednesday, September 9. The rating was maintained by Oppenheimer on Thursday, August 6 with “Outperform”. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The firm earned “Hold” rating on Thursday, September 3 by Zacks. BMO Capital Markets initiated the shares of AFMD in report on Tuesday, April 12 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, August 1 by Oppenheimer. The stock has “Market Perform” rating by Leerink Swann on Thursday, May 19. As per Monday, August 10, the company rating was upgraded by Zacks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>